Physician profile
Mohammed Shafi
NPI 1740398270
$7,165.36
in general payments reported to CMS, 2019-2025
31 companies · $1,147 in 2025
The $1,147 reported for 2025 was more than what 89% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $604 · 2020: $477 · 2021: $939 · 2022: $1,132 · 2023: $1,478 · 2024: $1,389 · 2025: $1,147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,930 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,929.64 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,570.81 | 2019-2025 | Linzess, Rinvoq, Viberzi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,130.66 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Janssen Biotech, INC. | $859.08 | 2021-2025 | Stelara, Tremfya, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $583.88 | 2019-2025 | Entyvio, Eohilia |
| Genzyme Corporation | $347.86 | 2022-2024 | |
| Phathom Pharmaceuticals, INC. | $275.88 | 2024-2025 | Voquezna |
| Orphalan INC | $229.00 | 2024-2025 | Cuvrior |
| Pfizer INC. | $185.38 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $184.79 | 2023-2024 | Dupixent |
| Braintree Laboratories, INC. | $180.75 | 2019-2024 | Sutab, Suflave |
| Ironwood Pharmaceuticals, INC | $176.99 | 2019-2024 | Linzess |
| Gilead Sciences, INC. | $175.83 | 2019-2024 | |
| Ferring Pharmaceuticals INC. | $167.07 | 2019-2023 | Rebyota |
| Lilly USA, LLC | $161.47 | 2024-2025 | Omvoh |
| Redhill Biopharma INC. | $124.52 | 2021-2023 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $122.19 | 2024-2025 | Zenpep |
| Ardelyx, INC. | $97.51 | 2022-2023 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $86.86 | 2020-2022 | |
| Madrigal Pharmaceuticals | $74.16 | 2024-2025 | Rezdiffra, Resmetirom |
| Intra-Sana Laboratories | $72.06 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.96 | 2023-2024 | Cyltezo |
| Qol Medical, LLC | $61.30 | 2019-2024 | Sucraid |
| Shionogi INC | $55.89 | 2019 | |
| Celgene Corporation | $37.10 | 2022-2024 | Zeposia |
| Alfasigma USA, INC. | $33.56 | 2020 | |
| Sandoz INC. | $20.64 | 2023 | Hyrimoz |
| Medtronic, INC. | $19.51 | 2024 | Gi Genius |
| Novo Nordisk INC | $19.34 | 2025 | Wegovy |
| Blueprint Medicines Corporation | $17.61 | 2023 | |
| Ethicon US, LLC | $12.93 | 2019 | |
| Allergan, INC. | $11.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammed Shafi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.